Question 1

What is Autolus Therapeutics?

Accepted Answer

Autolus Therapeutics is a Company.

Question 2

How often does Autolus Therapeutics appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 29 articles.

Question 3

When was Autolus Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was Autolus Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 13, 2026.

Question 5

What is Autolus Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Autolus Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Autolus Therapeutics?

Accepted Answer

UK CAR T-cell Lupus Remission (Jun 11, 2026, 17 articles).

Question 8

How did the "UK CAR T-cell Lupus Remission" event impact Autolus Therapeutics?

Accepted Answer

Autolus Therapeutics>>> developed obecabtagene autoleucel (obe-cel), the CAR-T therapy used in the successful lupus trial, positioning it as a leader in cellular therapies.

Question 9

How did the "Pliant Therapeutics appoints two directors" event impact Autolus Therapeutics?

Accepted Answer

Autolus Therapeutics is mentioned as a current board seat for Iannone; not directly affected by this event.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.